The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma ...
So far only three GLP-1 drugs have been approved to treat obese or overweight individuals: liraglutide and semaglutide, ...
Lung Cancer is a complex and devastating disease with over 200,000 new cases in 2024 alone. Small Cell Lung Cancer, or SCLC, is one of the most aggressive cancers out there, ...
US FDA grants Breakthrough Device Designation to Roche’s blood test measuring Lp(a), a key marker for hereditary cardiovascular risk: Basel Thursday, May 23, 2024, 13:00 Hrs [IS ...
A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin ...